Can AI Drive Peloton’s Comeback?

In this episode of Motley Fool Money, Travis Hoium, Rachel Warren, and Jon Quast discuss Pfizer's acquisition of Metsera and its implications for the competitive obesity treatment market, focusing on GLP-1 drugs and potential impacts on companies like Eli Lilly and Novo Nordisk, as well as telehealth services like Hims and Hers. They then shift to Peloton's potential comeback, analyzing its subscription growth, cost-cutting measures, and new AI-powered fitness strategies, debating whether it's a worthwhile turnaround stock. Finally, they examine Circle's impressive results with USDC, the revenue distribution with Coinbase, and the potential disruption of traditional payment systems through Circle's new ARK blockchain and the broader tokenization of financial assets.